Objective:

To evaluate the impact of perfluorohexyloctane ophthalmic solution (PFHO) on preoperative biometry and dry eye symptoms in cataract surgery patients.

Key Findings:

• PFHO treatment did not negatively affect refractive outcomes; 82.6% of patients were within ±0.50 diopters of predicted refraction after treatment.
• Total corneal fluorescein staining improved significantly, with 75.8% of patients showing no central corneal staining after 30 days of PFHO therapy.
• Eye dryness scores improved from 62.3 to 25.9, and OSDI scores normalized from 51.9 to 11.9 by the end of the study.
• IOL calculation accuracy improved, with 84% of patients within ±0.5 diopters post-treatment compared to 72% at baseline.
• Best-corrected visual acuity (BCVA) of 20/20 or better increased from 86% to 92% after the postoperative treatment period.

Interpretation:

PFHO effectively treats dry eye disease without compromising critical measurements for cataract surgery, enhancing both ocular surface health and visual outcomes.

Limitations:

• The study may benefit from a larger patient population and an untreated control arm.
• Long-term outcomes beyond the 60-day follow-up period were not assessed.

Conclusion:

Aggressive treatment of dry eye with PFHO can improve patient comfort and surgical outcomes in cataract surgery, emphasizing the importance of ocular surface optimization.